Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

被引：0

作者：

van Beers, Erik ^{[1
]}

van Vliet, Martin ^{[1
]}

de Best, Leonie ^{[1
]}

Anderson, Kenneth C. ^{[2
]}

Chari, Ajai ^{[3
]}

Jagganath, Sundar ^{[4
]}

Jakubowiak, Andrzej ^{[5
]}

Kumar, Shaji K. ^{[6
]}

Lebovic, Daniel ^{[7
]}

Levy, Joan ^{[8
]}

Auclair, Daniel ^{[8
]}

Lonial, Sagar ^{[9
]}

Reece, Donna ^{[10
]}

Richardson, Paul G. ^{[11
]}

Siegel, David ^{[12
]}

Stewart, A. Keith ^{[13
]}

Trudel, Suzanne ^{[14
]}

Vij, Ravi ^{[15
]}

Zimmerman, Todd ^{[16
]}

Fonseca, Rafael ^{[13
]}

机构：

[1] SkylineDx, Rotterdam, Netherlands

[2] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[3] Icahn Sch Med Mt Sinai, Hematol & Med Oncol, New York, NY 10029 USA

[4] Mt Sinai Med Ctr, New York, NY 10029 USA

[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[6] Mayo Clin, Div Hematol, Rochester, MN USA

[7] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[8] Multiple Myeloma Res Fdn, Norwalk, CT USA

[9] Emory Univ, Winship Canc Inst, Div BMT, Atlanta, GA 30322 USA

[10] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

[11] Harvard Univ, Sch Med, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[12] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[13] Mayo Clin, Scottsdale, AZ USA

[14] Princess Margaret Canc Ctr, Toronto, ON, Canada

[15] Washington Univ, St Louis, MO USA

[16] Univ Chicago, Chicago, IL 60637 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial
Kuiper, Rowan
Zweegman, Sonja
van Duin, Mark
van Vliet, Martin H.
van Beers, Erik H.
Dumee, Belinda
Vermeulen, Michael
Koenders, Jasper
van der Holt, Bronno
Visser-Wisselaar, Heleen
Hansson, Markus
van der Velden, Annette W. G.
Beverloo, H. Berna
Stevens-Kroef, Marian
Levin, Mark-David
Broijl, Annemiek
Waage, Anders
Sonneveld, Pieter
BLOOD ADVANCES, 2020, 4 (24) : 6298 - 6309
[32] ISS stage and network risk score to predict benefits of multiple myeloma treatment options.
Liu, Yu
Wang, Li
Yu, Haocheng
Parekh, Samir S.
Schadt, Eric
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety
Nadeem, Omar
Redd, Robert
Stampleman, Laura V.
Matous, Jeffrey V.
Yee, Andrew J.
Zonder, Jeffrey A.
Kin, Andrew
Rosenblatt, Jacalyn
Bustoros, Mark
Prescott, Julia
Savell, Alexandra
Guimond, Kathleen
Frey, Erin
Styles, Rachel
Bielawski, Adrienne
Boehner, Cody J.
Kham, Nang
Sperling, Adam S.
Bianchi, Giada
Laubach, Jacob P.
Castillo, Jorge J.
Munshi, Nikhil C.
Anderson, Kenneth C.
Richardson, Paul G.
Trippa, Lorenzo
Ghobrial, Irene M.
BLOOD, 2019, 134
[34] Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma
Ria, R
Falzetti, F
Ballanti, S
Minelli, O
Di Lanni, M
Cimminiello, M
Vacca, A
Dammacco, F
Martelli, MF
Tabilio, A
HEMATOLOGY JOURNAL, 2004, 5 (02) : 118 - 122
[35] Study of Risk Factors for the Occurrence of Infection in Multiple Myeloma: Case-Control Study in Myeloma Patients
Niang, Elhadji Daouda
Sarr, Khadim
Thiam, Amy
Ciss, Modou Moustapha
Thiam, Awa
Niang, Adjaratou Thiane Diane
Camara, Marieme Lolita
Fall, Seynabou
Ndiaye, Fatou Samba Diago
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2025,
[36] Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group
Bustoros, Mark
Kastritis, Efstathios
Sklavenitis-Pistofidis, Romanos
Liu, Chia-Jen
Hornburg, Kalvis
Kanellias, Nikolaos
Kim, Geon
Liu, David
Gavriatopoulou, Maria
Marinac, Catherine R.
Roussou, Maria
Migkou, Magdalini
Noonan, Kimberly
Reyes, Kaitlen
Rivotto, Bradley
Neuse, Carl Jannes
Ziogas, Dimitrios C.
Laubach, Jacob
Terpos, Evangelos
Anderson, Kenneth C.
Richardson, Paul G.
Ghobrial, Irene M.
Dimopoulos, Meletios A.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) : E146 - E149
[37] A prospective clinical study evaluating current models for risk of progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM).
Cherry, Benjamin M.
Korde, Neha
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Yancey, Mary Ann
Mulquin, Marcia
Maric, Irina
Calvo, Katherine R.
Braylan, Raul
Stetler-Stevenson, Maryalice
Yuan, Constance
Tembhare, Prashant
Zingone, Adriana
Costello, Rene
Roschewski, Mark J.
Landgren, Ola
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[38] A prospective study of circulating adipokine levels and risk of multiple myeloma
Hofmann, Jonathan N.
Liao, Linda M.
Pollak, Michael N.
Wang, Ye
Pfeiffer, Ruth M.
Baris, Dalsu
Andreotti, Gabriella
Lan, Qing
Landgren, Ola
Rothman, Nathaniel
Purdue, Mark P.
BLOOD, 2012, 120 (22) : 4418 - 4420
[39] Study identifies risk factors for progression of smoldering multiple myeloma
Nature Clinical Practice Oncology, 2007, 4 (10): : 560 - 561
[40] Fracture risk with multiple myeloma: A population-based study
Melton, LJ
Kyle, RA
Achenbach, SJ
Oberg, AL
Rajkumar, SV
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (03) : 487 - 493

← 1 2 3 4 5 →